Condition
Hyperlipoproteinemia Type I
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Treatment Research
2 treatments under study, led by Cat2003
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.9% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02767531Phase 2CompletedPrimary
Orlistat for the Treatment of Type I Hyperlipoproteinemia
NCT02098278Phase 2Completed
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
NCT01447901TerminatedPrimary
Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
Showing all 3 trials
Research Network
Common Treatments
- Cat20031
- Orlistat1
Active Sponsors
- Catabasis Pharmaceuticals1
- Amsterdam Molecular Therapeutics1
- University of Texas Southwestern Medical Center1
- ICON plc1
Top Investigators
ECOGENE-21 Clinical Trial Center
University of Texas
Related Conditions
- Hypertriglyceridemia2
- Lipoprotein Lipase Deficiency Familial1
- Chylomicronemia Familial1